Key Points
- Venrock Healthcare Capital Par purchased 39,796 Lycia Therapeutics shares at an average price of $26.62, investing approximately $1.06 million and increasing its ownership by 0.59%.
- Following the transaction, Venrock directly held 6.83 million shares valued at roughly $181.7 million. The purchase was disclosed in an SEC filing, as required for shareholders owning at least 10% of the company.
- The shareholder also bought nearly 2 million shares on October 26 for approximately $35.2 million, while LYCA opened at $26.11 and has traded between $22.19 and $36.49 over the past year.
Lycia Therapeutics, Inc. (NASDAQ:LYCA - Get Free Report) major shareholder Venrock Healthcare Capital Par acquired 39,796 shares of the firm's stock in a transaction dated Tuesday, October 27th. The shares were purchased at an average cost of $26.62 per share, for a total transaction of $1,059,369.52. Following the completion of the acquisition, the insider directly owned 6,825,233 shares in the company, valued at approximately $181,687,702.46. This represents a 0.59% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Large shareholders that own at least 10% of a company's shares are required to disclose their transactions with the SEC.
Venrock Healthcare Capital Par also recently made the following trade(s):
- On Monday, October 26th, Venrock Healthcare Capital Par bought 1,952,705 shares of Lycia Therapeutics stock. The shares were purchased at an average price of $18.04 per share, with a total value of $35,226,798.20.
- On Friday, October 23rd, Venrock Healthcare Capital Par bought 52,939 shares of Lycia Therapeutics stock. The stock was acquired at an average cost of $25.91 per share, with a total value of $1,371,649.49.
Lycia Therapeutics Price Performance
LYCA stock opened at $26.11 on Wednesday. Lycia Therapeutics, Inc. has a fifty-two week low of $22.19 and a fifty-two week high of $36.49.
Lycia Therapeutics, Inc is a biotechnology company developing medicines designed to eliminate disease-causing proteins from cells. The company's approach is based on lysosome-targeting chimeras, or LYTACs, which are engineered molecules intended to direct extracellular and cell-surface proteins to lysosomes for degradation.
Lycia's technology is intended to address disease targets that may be difficult to inhibit with conventional drugs, including proteins located outside cells or embedded in cell membranes.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
